

1- Agincourt

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lipids)
<b>Framingham (BMI)</b>					
kappa (95%CI)	0.02 (0.12-0.29)*	0.03 (0.02-0.04)**	0.41 (0.37-0.45)**	0.61 (0.57-0.65)**	0.53 (0.49-0.57)**
Agreement %	58.7%	58.7%	71.8%	80.3%	76.7%
Spearman's correlation	0.298**	0.350**	0.680**	0.762**	0.739**
<b>Framingham (lipids)</b>					
kappa	0.07 (0.05-0.09)**	0.12 (0.08-0.15)**	0.63 (0.59-0.68)**	0.60 (0.56-0.65)**	
Agreement %	74.8%	75.6%	86.5%	83.9%	
Spearman's correlation	0.355**	0.399**	0.355**	0.399**	
<b>Globorisk (office)</b>					
kappa	0.07 (0.05-0.10)**	0.08 (0.06-0.10)**	0.59 (0.54-0.64)**		
Agreement %	74.0%	73.6%	84.5%		
Spearman's correlation	0.339**	0.418**	0.710**		
<b>Globorisk (lab)</b>					
kappa	0.10 (0.07-0.13)**	0.18 (0.14-0.23)**			
Agreement %	80.6%	81.9%			
Spearman's correlation	0.401**	0.442**			
<b>WHO-CVD (office)</b>					
kappa	0.56 (0.33-0.68)**				
Agreement %	97.2%				
Spearman's correlation	0.595**				

2- Dikale

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lipids)
<b>Framingham (BMI)</b>					
kappa (95%CI)	0.04 (0.03-0.06)**	0.04 (0.03-0.06)**	0.45 (0.41-0.50)**	0.57 (0.53-0.62)**	0.57 (0.52-0.62)**
Agreement %	66.5%	66.5%	77.1%	81.4%	81.0%
Spearman's correlation	0.333**	0.321**	0.708**	0.764**	0.763**
<b>Framingham (lipids)</b>					
kappa	0.11 (0.08-0.15)**	0.12 (0.08-0.16)**	0.63 (0.58-0.68)**	0.57 (0.52-0.62)**	
Agreement %	78.5%	78.7%	87.7%	84.5%	
Spearman's correlation	0.384**	0.368**	0.384**	0.368**	
<b>Globorisk (office)</b>					
kappa	0.12 (0.07-0.16)**	0.09 (0.06-0.11)**	0.61 (0.56-0.67)**		
Agreement %	79.4%	78.8%	87.4%		
Spearman's correlation	0.349**	0.406**	0.703**		
<b>Globorisk (lab)</b>					
kappa	0.13 (0.09-0.17)**	0.14 (0.10-0.19)**			
Agreement %	82.9%	83.2%			
Spearman's correlation	0.445**	0.427**			
<b>WHO-CVD (office)</b>					
kappa	0.58 (0.44-0.71)**				
Agreement %	97.5%				
Spearman's correlation	0.608**				

3- Nainobi

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lipids)
<b>Framingham (BMI)</b>					
kappa (95%CI)	0.05 (0.03-0.07)**	0.05 (0.03-0.07)**	0.11 (0.09-0.15)**	0.09 (0.07-0.12)**	0.57 (0.53-0.61)**
Agreement %	77.9%	77.8%	78.5%	78.2%	86.4%
Spearman's correlation	0.277**	0.303**	0.377**	0.381**	0.692**
<b>Framingham (lipids)</b>					
kappa	0.11 (0.07-0.15)**	0.12 (0.08-0.16)**	0.19 (0.15-0.24)**	0.20 (0.15-0.25)**	
Agreement %	85.6%	85.7%	86.0%	86.4%	
Spearman's correlation	0.319**	0.331**	0.319**	0.331**	
<b>Globorisk (office)</b>					
kappa	0.60 (0.48-0.72)**	0.74 (0.64-0.84)**	0.62 (0.52-0.72)**		
Agreement %	98.3%	98.8%	97.7%		
Spearman's correlation	0.665**	0.775**	0.636**		
<b>Globorisk (lab)</b>					
kappa	0.59 (0.47-0.70)**	0.55 (0.43-0.66)**			
Agreement %	98.0%	97.7%			
Spearman's correlation	0.663**	0.610**			
<b>WHO-CVD (office)</b>					
kappa	0.74 (0.62-0.86)**				
Agreement %	99.2%				
Spearman's correlation	0.761**				

4- Nanoro

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lipids)
<b>Framingham (BMI)</b>					
kappa (95%CI)	0.01 (0.00-0.02)**	0.01 (0.00-0.02)**	0.32 (0.27-0.37)**	0.49 (0.35-0.45)**	0.48 (0.43-0.53)**
Agreement %	81.9%	81.9%	85.2%	86.5%	87.6%
Spearman's correlation	0.125**	0.137**	0.524**	0.581**	0.622**
<b>Framingham (lipids)</b>					
kappa	0.04 (0.00-0.08)**	0.05 (0.01-0.09)*	0.19 (0.15-0.24)**	0.50 (0.43-0.56)**	
Agreement %	91.5%	91.6%	93.4%	92.9%	
Spearman's correlation	0.165**	0.180**	0.165**	0.180**	
<b>Globorisk (office)</b>					
kappa	0.05 (0.05-0.09)**	0.04 (0.01-0.08)*	0.62 (0.55-0.69)**		
Agreement %	93.6%	93.5%	95.7%		
Spearman's correlation	0.194**	0.216**	0.654**		
<b>Globorisk (lab)</b>					
kappa	0.05 (0.01-0.09)*	0.07 (0.01-0.13)*			
Agreement %	94.6%	94.8%			
Spearman's correlation	0.216**	0.232**			
<b>WHO-CVD (office)</b>					
kappa	0.73 (0.43-1.00)**				
Agreement %	99.8%				
Spearman's correlation	0.730**				

5- Navrogo

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lipids)
<b>Framingham (BMI)</b>					
kappa (95%CI)	0.02 (0.01-0.23)**	0.03 (0.02-0.04)**	0.42 (0.38-0.46)**	0.51 (0.47-0.54)**	0.41 (0.37-0.45)**
Agreement %	69.8%	69.8%	77.7%	79.7%	77.8%
Spearman's correlation	0.207**	0.277**	0.641**	0.668**	0.655**
<b>Framingham (lipids)</b>					
kappa	0.08 (0.04-0.11)**	0.15 (0.10-0.19)**	0.57 (0.52-0.62)**	0.49 (0.45-0.53)**	
Agreement %	85.4%	86.0%	88.3%	84.1%	
Spearman's correlation	0.266**	0.340**	0.266**	0.340**	
<b>Globorisk (office)</b>					
kappa	0.03 (0.02-0.05)**	0.06 (0.03-0.07)**	0.69 (0.65-0.73)**		
Agreement %	78.2%	78.2%	90.0%		
Spearman's correlation	0.234**	0.321**	0.760**		
<b>Globorisk (lab)</b>					
kappa	0.04 (0.03-0.06)**	0.10 (0.07-0.14)**			
Agreement %	83.4%	83.9%			
Spearman's correlation	0.269**	0.335**			
<b>WHO-CVD (office)</b>					
kappa	0.60 (0.46-0.75)**				
Agreement %	98.8%				
Spearman's correlation	0.632**				

6- Soweto

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lipids)
<b>Framingham (BMI)</b>					
kappa (95%CI)	0.03 (0.02-0.37)**	0.04 (0.03-0.05)**	0.49 (0.45-0.52)**	0.63 (0.61-0.68)**	0.51 (0.47-0.54)**
Agreement %	56.4%	56.7%	73.4%	81.0%	72.8%
Spearman's correlation	0.333**	0.398**	0.746**	0.809**	0.687**
<b>Framingham (lipids)</b>					
kappa	0.06 (0.4-0.07)**	0.09 (0.07-0.11)**	0.56 (0.52-0.59)**	0.53 (0.49-0.56)**	
Agreement %	64.0%	63.7%	79.0%	76.4%	
Spearman's correlation	0.347**	0.391**	0.347**	0.391**	
<b>Globorisk (office)</b>					
kappa	0.07 (0.05-0.09)**	0.08 (0.07-0.10)**	0.61 (0.57-0.64)**		
Agreement %	68.5%	68.2%	82.4%		
Spearman's correlation	0.349**	0.462**	0.749**		
<b>Globorisk (lab)</b>					
kappa	0.09 (0.07-0.11)**	0.17 (0.13-0.20)**			
Agreement %	74.4%	75.8%			
Spearman's correlation	0.422*	0.461**			
<b>WHO-CVD (office)</b>					
kappa	0.51 (0.42-0.59)**				
Agreement %	95.5%				
Spearman's correlation	0.545**				

\*p<0.05  
\*\*p<0.0001

<0.4 poor  
0.41-0.60 moderate  
0.61-0.80 substantial  
>.80 excellent